Abstract: The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.
Type:
Grant
Filed:
May 4, 1998
Date of Patent:
March 13, 2001
Assignee:
Pacific Northwest Cancer Foundation
Inventors:
Gerald P. Murphy, Alton L. Boynton, Eric H. Holmes, Robert J. Barren, III
Abstract: Methods and compositions for use of human dendritic cells to activate T cells for immunotherapeutic responses against primary and metastatic prostate cancer are disclosed. In one embodiment, human dendritic cells, after exposure to a prostate cancer antigen or specific antigenic peptide, are administered to a prostate cancer patient to activate the relevant T cell responses in vivo. In an alternate embodiment, human dendritic cells are exposed to a prostate cancer antigen or specific antigenic peptide in vitro and incubated or cultured with primed or unprimed T cells to activate the relevant T cell responses in vitro. The activated T cells are then administered to a prostate cancer patient. Methods and compositions for human dendritic cells with extended life span and cryopreserved dendritic cells are disclosed.
Type:
Grant
Filed:
July 31, 1995
Date of Patent:
August 4, 1998
Assignee:
Pacific Northwest Cancer Foundation
Inventors:
Gerald P. Murphy, Alton L. Boynton, Benjamin A. Tjoa